Targeting alloantibody production with bortezomib: does it make more sense?

Clinical transplants

Volumn , Issue , 2010, Pages 397-403

  Lee, Iris ^a   Constantinescu, Serban ^b   Gillespie, Avrum ^b   Rao, Swati ^b   Silva, Patricio ^b   Birkenbach, Mark ^b   Leech, Stephen ^b   Karachristos, Andreas ^b   Daller, John A ^b   Sifontis, Nicole M ^b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; BORONIC ACID DERIVATIVE; BORTEZOMIB; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; PROTEASOME; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ARTICLE; BIOPSY; BLOOD; CELLULAR IMMUNITY; DRUG ANTAGONISM; DRUG EFFECT; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGY; KIDNEY TRANSPLANTATION; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; TIME; TREATMENT OUTCOME;

BIOPSY; BORONIC ACIDS; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 79960051703     PISSN: 08909016     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)